IMMUNOLOGY
The gastrointestinal tract remains a unique port of entry for a variety of organisms which ultimately result in diarrhoea and wasting in the HIV infected patient. By definition, many enteric pathogens infect the gastrointestinal tract by the faecal oral routẽ esulting in the high frequency of these infections In homosexual males" as well as inhabitants of the Third World, where sanitation may be poor. Oearly, a decline in intestinal mucosal defence would predispose patients to common infections in the gastrointestinal tract. Infected individuals with decreased mucosal immunity would also be likely to suffer severe and chronic manifestations of these infections. For example, diarrhoea and malabsorption znay occur in individuals with common variable immunodeficiency which is characterized by ã~c rease in immunoglobulin production, and dim-inIShed antibody responses and T-cell function. Ent~ric infections responsible for these symptoms in patIents with common variable immunodeficiency mclude giardiasis, bacterial overgrowth and occasionally strongyloidiasis4.
Studies of enteric immunity in HIV infected patients have shown an expected decrease in the total number of mucosal cells as well as a decreased D4 to COB suppressor T-cell ratio in the small mte~tinallamina propria 5 ,6. Of note, the density of la~a propria mononuclear cells increases in this group". Local immunoglobulin deficiency also probably occurs, with decreased density of IgÃ cr~g plasma cells present in the small intestinal arnina propria'. These findings may in part explain the susceptibility of HIV infected patients to intestinal infections.
INFECTIONS
A wide variety of .aetiologies may be responsible symptoms of small intestinal disease in HIV infected patients. These include viruses, bacteria, Table 1) . The distribution of these organisms in patients with AIDS is markedly dissimilar to those seen in non-HIV infected homosexual population, stressing the role that decreased mucosal defence plays in the development of these infections". A number of studies have addressed the prevalence of various infections in Hlv-mfected patients1,8.9. Since patient selection and methodology varies between these studies, the actual prevalence of clinically significant infections with various organisms remains unclear.
VIRAL PATHOGENS
Cytomegalovirus (CMV) is the most common virus to infect the gastrointestinal tract in patients with AlDSIO. Small intestinal involvement generally occurs in the setting of colonic and/or oesophageal infection11. CMV enteritis may result in intractable nausea, diarrhoea and malabsorption. Mucosal inflammation, oedema, and ulcerations result from CMV infections, although the pathogenic mechanisms for the development of these findings is unknown12. Cases of isolated ileal involvement with CMV have been reported-'. All information regarding pathogenesis and treatment of small intestinal manifestations of CMV must be gathered from studies on CMV colitis. CMV colitis is characterized by diarrhoea and fever. Gastrointestinal bleeding necrosis and perforation are rarer manifestations of infectionl", Endoscopic lesions include patchy as well as diffuse inflam-mation12. Advanced CMV infections of the gastrointestinal tract may result in haemorrhagic bowel necrosisv'. In open labelled'" and placebo-controlled I6 trials, intravenous therapy with gancyclovir 5 mg/kg for 14 days has been shown to be effective for CMV colitis. Several open labelled trials have shown efficacy of foscarnet therapy for CMV oesophagitis and colitis l 7,18 including those who failed therapy with gancyclovir'". Foscarnet doses varied from 90-180 mg/kg per day for 2-4 weeks. Foscamet is administered in combination with saline hydration.
Some authors have investigated the role of enteroviruses as a cause of unexplained diarrhoea in HIV infected patients. Using enzyme-linked immunosorbent assays, electron microscopy and cell cultures, rifampin 600 mg, ciprofloxacin 750mg and ethambu-tol25 mg/kg per day resulted in less rapid decline in patients with disseminated MAl when compared to placebos". Azithromycin 500 mg per day for 10-30 days has been shown to reduce MAl bacteraemiav.
PARASITIC INFECTIONS
Cryptosporidium is an intestinal protozoan parasite. It is a common cause of chronic diarrhoea in AIDS patients, usually occurring late in the course of the disease as immunological deterioration progresses. Infections may be associated with a severe wasting syndrome and voluminous stools 31.32. Malabsorption of carbohydrates and vitamin B12 are associated with cryptosporidial infections-'. The mechanism producing the clinical manifestations of these infections are unclear, although villous atrophy, which has been commonly described in cryptosporidial infections, probably plays a roleM. Historically, treatments for cryptosporidial infections have concentrated on supportive care with symptomatic therapy for diarrhoea and nutritional supplementation. Open labelled trials of a variety of treatments for cryptosporidiosis have been reported (see Table 2 ). Placebo-controlled, randomized studies of paromomycin, letazauril, bovine anticryptosporidial Immunoglobulin and azithromycin are under way49.
Isospora belli
This treatable form of coccidian parasitic infection OCcurs commonly in Third World countries, as a result of poor sanitation and contamination of food and drinking water. It has been seen in up to 15% of AIDS patients in Haiti, but in fewer than 0.2% of AIDS patients in the United States of America, althou~h the latter figure is probably an underestimation ,Symptoms resemble infection with crypto-spOridium, however, isospora is sensitive to both tritnethaprim-sulfamethoxazole and pyrimethamine. Recommended doses are trimethaprim 160 mg and sulfamethaxazole 800 mg 4 times a day for 10 days or pyrimethamine and pyrimethamine 75 mg per day plus folinic acid 10 mg per day for 1-4 weeks. Relapses are common and maintenance therapy may be required.
Microsporidium
The recognition that microsporidiosis is a common cause of chronic diarrhoea in some populations of infected patients has led to improved technologỹ n l~entifying this organism 49 ,50, 52 and octreotide 500 mcg r.l.d. (53) have been reported.
Giardia lamblia
Although this large flagellate protozoa is commonly seen in homosexual males, due to faecal oral route of acqUiSition, the clinical manifestations of giardiasis are variable in the mv infected patient. In fact, some have questioned whether giardia are pathogenic in this population 54 • In our experience, HIV infected patients with chronic diarrhoea in whom giardia are isolated from the stool show a variable improvement in symptoms after eradication of the organism.
Amoebiasis
Carriage of Entamoeba histolytica and other non-patho~enic amoebas is common in homosexual males ,55. These organisms have also been found in some series of HIV infected patients with diarrhoea", It remains unclear whether amoeba produce symptoms of diarrhoea in HIV-infected patients 54 , 
MISCELLANEOUS
Disseminated infections with Strongyloides stercoralis also involving the small intestine has been described 56 • A small bowel mass due to an extrapulmonary infection with Pneumocystis carinii presenting as an acute abdomen has been reported". LYMPHOMA Non-Hodgkin's lymphoma of the gastrointestinal tract may occur in association with HIV infection 58 . Lymphomas have been identified throughout the entire gastrointestinal system, but the small intestine appears to be a common site of involvements".
HIV ENTEROPATHY
In 1984, Kotler et al. described a group of HIV infected patients with symptomatic small intestinal disease as characterized by chronic diarrhoea and weight 10ss60. Despite an aggressive work-up to determine the aetiology of this disorder, no viral bacterial or parasitic organisms were identified to explain these patients' symptoms. These patients were defined as having HIV enteropathy. By definition, HIV enteropathy implies that small intestinal disease is present. Although up to 80% of patients with AIDS will ultimately develop diarrhoeast, not all of these patients will have malabsorption, a specific indicator of small intestinal effectsof the disease. Most studies show that despite aggressive work-ups including upper and lower endoscopy, some mv infected patients will have no identified cause of diarrhoea. The prevalence of mv enteropathy in this group has varied from 15-66% in the recent literature 1 ,9,22,61,62. Utilizing electron microscopy of jejunal biopsies, Kotler et al. have frequently found microsporidiosis and crytosporidiosis in a large percentage of these patients 34 • Overall, after identification of these organisms, only 6 of 43 patients (14%) met the previous definition of HN enteropathy. Our group has not identified duodenal microsporidia in a group of 36 HN-infected patients with chronic diarrhoea despite performance of electron microscopy (unpublished).
The role of HN virus itself in producing enteropathy has been heatedly debated in the literature. A variety of techniques have been utilized to show that mv organisms are present in the small intestine in infected patients. Most authors suggest that HN is present in lamina propria lymphocytes and macrophages 63 ,64. Direct infection by HN of enterochromaffin cells has also been suggested'". This is an intriguing possibility considering evidence has been gathered that enteropathy may be associated with neuronal damage within the gastrointestinal tract«>. Ehrenpreis et al. have found HN in lamina propria mononuclear cells in late stage HN-infected patients with normal appearing enterocytes and microvillis", This may indicate that enteropathy is a functional enterocyte defect, possibly due to substances secreted by infected cells. Some authors have suggested that villous atrophy is responsible for the development of malabsorption in patients with HN enteropathy68. Our group has failed to find severe villous atrophy even in patients with marked small intestinal malabsorption of D-xylose, although low grade atrophy appears to be a common finding67.
The malabsorption of lipid may be an important contributory factor in the development of severe weight loss seen in patients with HIV enteropathy. Lipid accumulation has been identified in enterocytes 69 and also along the basal lateral membrane of enterocytes in the lamina propria'".
ROLE OFTHE SMALL INTESTINE IN THE AIDS WASTING SYNDROME
The AIDS Wasting Syndrome has been defined as a 'profound and involuntary weight loss of greater than 10% of base-line weight ... in the absence of concurrent illness or condition other than HIV that could explain these findings'70, Because a subgroup of patients with the AIDS Wasting Syndrome will have associated chronic diarrhoea with no identifiable pathogens, these patients may in fact represent a severe form of HIV enteropathy. Our group has studied D-xylose absorption in 19 HIVinfected patients with chronic diarrhoea and no identifiable pathogens. Patients who had developed the AIDS Wasting Syndrome in the prior 6 months had a significantly lower D-xylose absorption?". This finding suggests that small intestinal malabsorption has an important role in the development of the AIDS Wasting Syndrome in patients with chronic diarrhoea. On the other hand, the frequency of small intestine malabsorption in patients with the AIDS Wasting Syndrome who do not have gastrointestinal symptoms has yet to be studied. Because the AIDS Wasting Syndrome carries such a poor prognosis, it is possible that early identification of patients with small intestinal malabsorption prior to the development of profound wasting may be warranted in HIV-infected patients'",
DIAGNOSTIC AND THERAPEUTIC STRATEGIES
mv-infected patients initially presenting with symptoms with small intestinal disease (diarrhoea and weight loss) pose a difficult problem for clinicians involved in their care. On the one hand, intestinal infections are relatively common in these patients. On the other hand, it is clear that not all of these patients require an aggressive diagnostic work-up72. Our current recommended evaluation in these patients includes 3 stools for ova and parasites, including special staining for cryptosporidium and isospora. At least one stool specimen for culture and sensitivity should also be sent. If these initial studies are not diagnostic, performance of D-xylose test with a 25 g dose and a I-h serum D-xylose level is recommended. Our experience suggests that measurement of a 5 h urine D-xylose test is of little value, since it is abnormally low in most patients, whether overt malabsorptive symptoms are present or not. If the I-h serum D-xylose level is below normal « 20mgl dl), an upper endoscopy, small bowel biopsy, and aspirate for ova and parasites including cryptosporidium is performed. A I-h D-xylose level below 13 mg/dl also appears to be a marker for the AIDS Wasting Syndrome/I. Using upper endoscopy and stool studies alone, we have identified causative organisms in (17%) of 36 patients with chronic diarrhoea. At the same session as the upper endoscopy, sigmoidoscopy, or colonoscopy to evaluate for colitis also appears prudent. Patients in whom no organism is identified may subsequently require an upper GI X-ray with small bowel follow-through or a CT scan of the abdomen depending on clinical presentation (for example, if abdominal pain is present). Routine studies of pancreatic function have been essentially unremarkable in our experience which has been confirmed by other authors 73 . Measurement of daily stool volume may assist with the evaluation of severity of symptoms and can be used as a marker for response to therapy. It should be emphasized that many patients will remain with the diagnosis of HN enteropathy following a thorough diagnostic workup. All HN-infected patients with chronic diarrhoea should have a serum vitamin B12 level test, since BU deficiency is highly prevalent in this group74,75.
THERAPEUTIC STRATEGY
All patients with severe malabsorption noted on the 1 h serum D-xylose test should have aggressive nutritional therapy initiated. Potential sources of this therapy include nutritional supplements containing MCT oil, MCT oil alone, and or elemental formulas as tolerated. A low fat diet with MCT oil supplementation may be beneficial as well. Stool bulking agents such as psyllium help some patients. A clinical decision regarding intravenous hyperalimentation should also be made. Vitamin B 12 should be replaced parenterally if deficiency is identified.
For patients with AIDS Wasting Syndrome and chronic diarrhoea, therapy with octreotide (Sandostatin), or an opium containing compound is recommended since these patients generally fail conventional treatment with loperamide or diphenoxylate 71 • Other patients with less severe diarrhoea may be started on loperamide or diphenoxylate at 1 or 2 capsules per day and advanced to the maximum dose of B capsules per day. Octreotide doses are initiated at 50 /lg subcutaneously t.i.d. and should be increased to achieve a reasonable result (for example, a 50% reduction in stool volume). Doses of octreotide tend to be higher in patients with HIV related diarrhoea who mal require up to 1500p.g in 3 divided doses per day? . It should be noted that octreotide therapy may worsen steatorrhoea and may result in obstructive upper intestinal symptoms, especially when used in high doses. A Variety of experimental therapies for the AIDS wasting syndrome are under investigation?". 
